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APPENDIX
ANCESTRY INFORMATIVE MARKERS
Nine markers were selected from a panel established by Lao et al, 1 and 9 were unlinked markers from our data set with differences in minor allele frequency (MAF) between African Americans and European Americans that were greater than 0.3. These markers were rs1344870, rs1363448, rs1823718, rs1858465, rs1876482, rs2352476, rs722869, rs735612, and rs952718 from the study by Lao et al 1 ; and rs10473984, rs28536160, rs3761249, rs3779250, rs6472258, rs6999780, rs7307997, rs9866124, and rs1396862 from this project. Using STRUCTURE, version 2.0, 2 and a 4-population model, 20 000 burn-ins, 20 000 repetitions, and additional genotype data for these markers from Yorubans (YOR), participants in the Centre d'Etude du Polymorphisme Humain (CEPH) (CEU sample), and Han Chinese (CHB) individuals from the HapMap project (http://www.hapmap.org), we calculated the estimated proportion of African ancestry for each individual.
PERFORMANCE OF ANCESTRY INFORMATIVE MARKERS
The 18 ancestry informative markers selected to distinguish between the biogeographical ancestry from the 4 continental populations distinguished well between YOR, CEPH European (CEU), and CHB subjects with use of a 4-population model. The YOR (94.1% contribution from African Ancestry) and CHB (92.7% contribution from Asian ancestry) subjects were defined as 1 population each. The CEPH Europeans, however, were predicted to be admixed from the 2 remaining populations in the model (25.0% and 53.9%) as well as Asian ancestry (16.8%). This is likely due to the fact that the ancestry informative marker panel that was previously reported 1 had been selected to identify mostly Mediterranean Europeans as being from the European continental population group and thus did not perform well in individuals of mostly Northern European descent, such as the samples from CEPH. African ancestry, in contrast, was estimated to be very low in CEPH European and Han Chinese individuals, 2.8% and 2.1%, respectively, making this ancestry estimate the most robust. Within the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) sample, European Americans had on average a 3.8% estimated African ancestry (0.008%-72.2%, with 91.5% of individuals having Ͻ10% estimated African ancestry), African Americans had 81.8% (0.015%-98.3%, with 8.8% having Ͻ50% African ancestry), and Hispanic individuals had 7.6% (0.006%-89.3%, with 2.1% with Ͼ50% African ancestry) (eFigure).
GENETIC COVERAGE OF THE SNP PANEL PASSING QUALITY CONTROL
To assess the genetic coverage of the 73 singlenucleotide polymorphisms (SNPs) entering the analysis, we mapped the remaining SNPs to tagging SNPs selected for individuals from European descent (those in the CEU sample) in HapMap phase II data for an MAF of 5% or greater (unless noted otherwise) and an r 2 of 80% or greater. At least 5 kilobases (kb) of sequence upstream and downstream of the genes were included for the selection of tagging SNPs.
For AVP, 100% of the bins tagging the locus plus 10 kb at 5Ј and 3Ј of the gene as well as 2 additional SNPs not genotyped in HapMap have been included. For AVPR1A, 3 of the 4 bins are included. In HapMap phase II, no SNPs had been genotyped within 100 kb of the AVPR1B locus. Our study includes 10 SNPs within this locus, representing at least 4 independent bins. Owing to the lack of HapMap phase II SNPs, none of the current SNP arrays contain variants within this locus.
For the 10 kb surrounding the CRH locus, 1 of the 2 tags listed for CEU are included. On commercial SNP arrays, this region has very limited coverage in all arrays except Illumina, version 6.0, so that the 9 SNPs analyzed within this locus give more coverage than most of the current SNP arrays.
For the CRHR1 locus, we covered 6 of 7 bins (for an MAF of 10%), with the last bin containing only 1 SNP. For the CRHBP locus, we covered 6 of the 7 bins. The missing bin includes only rs11950140, with an MAF of 6% in the CEU sample. In addition to the HapMap tagging SNPs, we have genotyped 3 additional independent tagging SNPs, so that we cover more of the genetic variants within this locus than covered in HapMap phase II. In fact, our most associated SNP, rs10473984, is only genotyped on the Affymetrix 6.0 array, and no other arrays cover this SNP, even by the tagging approach. For the CRHR2 locus, 12 of the required 13 bins are covered. For the UCN locus, 2 tagging SNPs are shown for CEPH individuals within 10 kb of this gene. We have genotyped rs6721762 but are missing rs4665963. For the UCN2 locus, no SNP with an MAF greater than 5% is shown for CEPH subjects. The SNP included in our panel only reached an MAF greater than 5% in African Americans. For the UCN3 locus, we still describe 4 of the 5 required tags.
METHODS
SUMMARY OF EXCLUSION CRITERIA WITHIN STAR*D
Patients with bipolar, psychotic, or obsessive-compulsive disorders were excluded as were those with primary eating disorders, general medical conditions that contraindicated study medications, substance dependence requiring inpatient detoxification, and clear nonresponse or intolerance to any protocol antidepressant during a current episode or those who were pregnant or breastfeeding.
DRUG TOLERABILITY
In brief, all subjects who elected to continue taking citalopram to the end of the level 1 treatment period were considered tolerant, whereas subjects who refused to continue taking citalopram or who left the study because of adverse effects were considered intolerant. The remaining subjects were classified on the basis of their Global Rating of Side Effect Burden score as probably tolerant (no more than moderate adverse effect burden) or probably intolerant (more than moderate adverse effect burden Burden scores were classified according to whether they were treated with citalopram for less than 4 weeks (probably intolerant) or 4 or more weeks (probably tolerant).
SELECTION OF TAGGING SNPs
One hundred seventeen tagging SNPs were selected. Haploview, 3 version 3.2, was used to identify tagging SNPs for each gene covering at least 5 kb 5Ј to 5 kb 3Ј of each gene. We used data from the CEPH sample of European descent in HapMap version II as well as data from 47 European Americans and 47 African Americans from the northeast of the United States to derive tagging SNPs. For tagging SNP selection, we used a cutoff of 5% for the MAF and set the r 2 threshold to 80%. A total of 117 SNPs were selected, which consisted of tagging SNPs as well as SNPs with prior evidence for potential association with depression-related or treatment-response phenotypes.
ADDITIONAL INFORMATION FOR LOW-DOSE DEXAMETHASONE SUPPRESSION TEST
For the selected 164 individuals, the mean age of this sample was 45.6 years (SD, 10.9 years), and 50.9% were female. All individuals had data concerning the Beck Depression Inventory, 4 the Posttraumatic Stress Disorder symptom scale, 5 and the Childhood Trauma Questionnaire 6 evaluated at the time of the test. DNA was extracted from whole blood using the Qiagen M48 biorobot system, and rs10473984 was genotyped using an Applied Biosystems TaqMan assay as described above.
Blood samples in the fasting state were obtained between 8 and 9 AM on day 1 for baseline serum cortisol and corticotropin concentrations. Subjects then received 0.5 mg of dexamethasone orally at 11 PM prior to blood draw on the second day; blood samples for serum cortisol and corticotropin concentration were collected again in the fasting state between 8 and 9 AM on the second day.
Serum cortisol was measured using commercially available radioimmunoassay kits (Diagnostic Systems Laboratories, Webster, Texas) from replicated samples and with interassay qualitycontrol measures. Serum corticotropin was measured using the radioimmunoassay kit from DiaSorin SpA (Sallugia, Italy). In the second-day serum samples, dexamethasone was assessed using a commercially available enzyme-linked immunosorbent assay kit from Neogen (Lexington, Kentucky).
